Coherus Oncology vs Editas Medicine
Coherus Oncology reported revenue of $42 million in fiscal 2025, about the same as Editas Medicine's $40 million in fiscal 2025. Coherus Oncology's revenue grew 59.8% in its latest year, and Editas Medicine's grew 25.4%. Coherus Oncology had an operating margin of -429.5%, against -394.9% at Editas Medicine.
Side by side
| Coherus Oncology | Editas Medicine | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $42M | $40M |
| Revenue growth | 59.8% | 25.4% |
| Revenue growth a year, last 5 years | −38.4% | −14.9% |
| Gross margin | 67.2% | — |
| Operating margin | −429.5% | −394.9% |
| Net margin | 398.4% | −395.0% |
| Free cash flow | — | −$166M |
| Free cash flow margin | — | −409.3% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 2.3% | 7.8% |
| Last close | $0.39 | $1.71 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $106,705 |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Coherus OncologyEditas Medicine
Operating margin
Percent of revenue
Coherus OncologyEditas Medicine
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Coherus OncologyEditas Medicine
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Coherus Oncology and Editas Medicine pages.